Kishan S Parikh

Journal Article Adv Ther · February 12, 2026 INTRODUCTION: Oral selexipag is indicated to delay disease progression and reduce risk of pulmonary arterial hypertension (PAH)-related hospitalization, as demonstrated in GRIPHON. There are situations when clinicians or patients may need or want to transi ... Full text Link to item Cite

Returning Individual-Level Urgent or Emergent Research Results to Participants: The Project Baseline Health Study Experience.

Journal Article Am J Med Open · June 2025 BACKGROUND: Returning results to research participants is increasingly recognized as an ethical mandate, yet little is known about best practices to optimally communicate urgent or emergent results. METHODS: We describe the development of and experience wi ... Full text Link to item Cite

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil.

Journal Article JHLT Open · November 2024 BACKGROUND: Patients with pulmonary arterial hypertension (PAH) and additional cardiac or pulmonary comorbidities have a poor prognosis and are frequently excluded from clinical trials. The purpose of this study was to evaluate outcomes of patients with pu ... Full text Open Access Link to item Cite

View All Publications

Education, Training & Certifications

Northwestern University, Feinberg School of Medicine · 2009 M.D.

Kishan S Parikh

Overview

Current Appointments & Affiliations

Recent Publications

Transitioning Prostacyclin Pathway Agents to Oral Selexipag in Patients with Pulmonary Arterial Hypertension: A Systematic Literature Review.

Returning Individual-Level Urgent or Emergent Research Results to Participants: The Project Baseline Health Study Experience.

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil.

Recent Grants

ALLAY-HF

REDUCE LAP-HF

Automated acute pulmonary embolism assessment from CT

Education, Training & Certifications